Amicus Therapeutics has been at the forefront of individualized medicine in the biotechnology industry. The company focuses on rare and orphan diseases treatment using technologies that are science driven to deliver ultimate benefits to the patients. Amicus believes that positioning themselves at the forefront of developing therapies for unmet needs it the only way to help the vast majorities of patients with rare devastating diseases. Therefore, the company has a robust development pipeline of other treatments for different genetic diseases.
As a global biotechnology company, Amicus Therapeutics has unique platform technologies in development for people with disorders such as lysosomal storage disorders (LSDs), and Pompe disease as well as skin disorders such as the epidermolysis Bullusa. Precisely, Amicus product development is based on advanced replacement therapy platform and concentrates on ERTs (Enzyme replacement therapies). In the recent years, the company has been noted to have the broadest portfolio of pharmacological chaperones in the industry (YourBeautyCraze).
Amicus Therapeutics has recently advanced its precision product Migalastat, in treating patients with Fabry disease (alpha-galactosidase A deficiency) a rare disorder where sphingolipids are not well metabolized. Previous Fabry disease therapies involved using ERT to manage the ailment, but Amicus Therapeutics therapy does not replace the enzymes, rather it helps the ones that are produced to work better (http://www.gcreport.com/amicus-therapeutics-announces-new-drug-application/). The company estimates that more than half of Fabry disease patient could benefit from this treatment.The company has also collaborated with GlaxoSmithKline as well as JCR pharmaceutical to investigation preclinical programs in other rare diseases such as the CDKL5 deficiency.
In 2009, Amicus faced a major financial setback after a termination of an agreement with The Shire, which led to a major corporate reconstruction. However, the company has consistently innovated new ERT products for Pompe diseases, LSD and Fabry diseases. Amicus therapeutics center of inventive science is the need of patients with rare diseases, so the company continues to develop new products that will make the difference in the lives of these patients as well as their caregiver.
More about Amicus Therapeutics on Crunchbase and Facebook
Osteo Relief Institutes founded in the year 2012. The nonsurgical relief for arthritis institute is the United States privately owned company. The Institute primary aim is to help patients avoid costly surgery treatments by offering secure and impressive joint pains medications that provide little to no procrastination such as the joint injection. The organization team comprises of highly trained staff in fields of patient care and communication. Osteo relief institute headquarters its medical practices in Wall, New Jersey.
Osteo Relief Institute is made up of a group of board-certified physicians and physical therapists that believe patients should be offered treatments to satisfaction (PositiveTheFacts). The institute is uniquely combined with FDA approved and cleared technologies equipment. The institute focuses on using the most advanced up-to-date technology to give its patients the edge in getting them lasting pain relief. Osteo relief is also made up of several centers in different locations independently owned.
Osteo Relief Institute, New Jersey provides Monmouth county and nearby areas with the non-surgical relief for their knee arthritis and spinal disc pain (http://alivenewspaper.com/2017/09/osteo-relief-institue/). Osteoarthritis is an unbearable situation that occurs in a lot of people as their bodies’ age. Osteoarthritis is the most chronic classification of arthritis and affects approximately 30 million individuals globally. The condition is severe, but with the correct treatment plan, a lot of patients can get help strengthening movements and minimal pain.
Fortunately, Osteo Relief Institute Nonsurgical treatment practice is believed be the most advanced and most efficient in the area. Osteo institute has invested in the most recent technology and types of equipment to provide accurate treatment to its patients. The nonsurgical medical institute offers risk-free first screening services to new patients.
The knee program helps patient to stay active all through and provides comfort with no or less pain. The New Jersey-based institute team delivers services to their patients in mind that every patient is unique and solves this by offering a wide selection procedure that is believed to satisfy all its different patients. The Osteo family is very affordable because it takes advantage of the advancing technology compared to surgery treatments which are costly.
More about Osteo Relief Institute on Crunchbase